Inkon Life completes acquisition of Changsha Kexin stake

INKON Life Technology (SZSE:300143) announced today the completion of its acquisition of a 51% equity interest in Changsha Kexin Cancer Hospital Co., Ltd. The acquisition, approved on March 27, 2025, sees INKON Life paying a total consideration of CNY 357 million for the majority stake. The transaction has now received all necessary regulatory approvals, including the updated business license issued by the Hunan Xiangjiang New Area Management Committee, and has been formally registered with the Administration for Market Regulation. With the completion of the deal, Changsha Kexin becomes a subsidiary of INKON Life and will be consolidated into the company’s financial statements.